Camrelizumab combined with anlotinib as second-line therapy for metastatic or recurrent small cell lung cancer: a retrospective cohort study
Shujing Shen(First Affiliated Hospital of Zhengzhou University), Ningning Yan(Suzhou Kowloon Hospital), Xingya Li(First Affiliated Hospital of Zhengzhou University), Sanxing Guo(First Affiliated Hospital of Zhengzhou University), Liang Xu(China Three Gorges University)
Cited by 7
Related Papers
Causes of Blindness and Visual Impairment in Urban and Rural Areas in Beijing
|Ophthalmology|2006|614
High Myopia and Glaucoma Susceptibility
|Ophthalmology|2006|592
Refractive Error in Urban and Rural Adult Chinese in Beijing
|Ophthalmology|2005|273
Genome-wide analysis of multi-ancestry cohorts identifies new loci influencing intraocular pressure and susceptibility to glaucoma
|Nature Genetics|2014|251
Anterior Chamber Depth and Chamber Angle and Their Associations with Ocular and General Parameters: The Beijing Eye Study
|American Journal of Ophthalmology|2008|247